< Back to previous page
Researcher
Frédéric Amant
- Disciplines:Gynaecology
Affiliations
- Gynaecological Oncology (Division)
Responsible
From1 Mar 2006 → Today - Gynaecological Oncology (Division)
Member
From1 Jan 2012 → Today
Projects
1 - 10 of 60
- Overcoming resistance to anti-PD1 blockade in uterine leiomyosarcomasFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Post-mortem tissue biobanking to illuminate end-stage ovarian cancer disease (ATLASOvCANCER)From1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Improving treatment of rare women’s cancers and conditions.From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- ProPOSE: Proton therapy in Pregnancy for Optimal, Safe and Effective cancer treatmentFrom1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Improving treatment of rare women’s cancers and conditions.From1 Oct 2023 → TodayFunding: BOF - ZAP BOF mandates
- Advisory Board Cancer Infertility Pregnancy (ABCIP)From1 Jan 2023 → 31 Dec 2023Funding: Other federal public and semi-governmental institutions
- ProPOSE: Proton therapy in Pregnancy for Optimal, Safe and Effective cancer treatmentFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Unique IsoPlexis technology for multiplexed single cell functional profilingFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Impact of prenatal exposure to cancer treatment during pregnancy and of chemotherapy for breast cancer on the brains: a multimodal MR imaging studyFrom1 Dec 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Defining the role of the tumor microenvironment in treatment resistance of OVArian cancer through patient-Derived EXplants (OVADEX)From1 Sep 2022 → TodayFunding: HORIZON.1.2 - Marie Skłodowska-Curie-actions (MSCA)
Publications
11 - 20 of 583
- Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab(2023)
Authors: Joosje Heimovaara, Frédéric Amant
Pages: 1790 - 1796 - European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors(2023)
Authors: Frédéric Amant, Sileny Han
Pages: 1621 - 1626 - A novel flavonol glycoside and six derivatives of quercetin and kaempferol from Clematis flammula with antioxidant and anticancer potentials(2023)
Authors: Frédéric Amant
- High accumulation of nivolumab in human breast milk: A case report(2023)
Authors: Frédéric Amant
- ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)(2023)
Authors: Vincent Vandecaveye, Frédéric Amant
Pages: 849 - 866 - An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy(2023)
Authors: Charlotte Maggen, Frédéric Amant
Pages: 5480 - 5484 - Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features(2023)
Authors: Beppe Floris, Kristel Van Calsteren, Patrick Neven, Sileny Han, Daniela Annibali, Diether Lambrechts, Liesbeth Lenaerts, Frédéric Amant
Pages: 3729 - 3743 - Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs(2023)
Authors: Frédéric Amant, Kristel Van Calsteren
Pages: 1157 - 1167 - Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach(2023)
Authors: Frédéric Amant
Pages: 969 - 980 - PROGNOSTIC FACTORS FOR OBSTETRIC AND ONCOLOGICAL OUTCOME IN PREGNANT WOMEN WITH CANCER Chemotherapy in pregnancy: from fetal safety to maternal efficacy(2023)
Authors: Charlotte Maggen, Frédéric Amant, Kristel Van Calsteren